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Abstract
Introduction: Primary tumors of seminal vesicles are rare and only a few cases have been reported. Diagnosis is
difficult due to the absence of early clinical signs. Prognosis is generally poor.
Case presentation: We present the case of a 70-year-old Caucasian man with a seminal vesicle mass and
concomitant lymph node metastasis detected by computed tomography and body positron emission
tomography/low-dose computed tomography scan carried out for evaluation of Lambert Eaton syndrome.
Transrectal ultrasound-guided biopsy showed a poorly differented neuroendocrine carcinoma with an
immunhistochemical profile similar to small cell lung cancer. Following chemotherapy the disease was stable and
active surveillance was initiated.
Conclusions: Lambert Eaton syndrome may be the initial symptom of a seminal vesicle mass. Diagnosis needs to
be obtained by transrectal biopsy and chemotherapy may delay progression of the tumor.
Introduction
Primary tumors of seminal vesicles are extremely rare. A
total of 51 documented cases of seminal vesicle carci-
noma in men between the ages of 19 and 90 years old
have been reported in the literature [1]. The first case
was presented by Lyons in 1925 [2]. Epithelial and
mesenchymal tumors have been described most often,
while fibromas, myomas and sarcomas are found even
less often [3]. Of all seminal vesicle tumors adenocarci-
noma is the most prevalent [1]. Primary seminal vesicle
tumors have to be clearly distinguished from a neoplasm
infiltrating from outside, e.g. prostate, rectal or bladder
cancer. Tumors of seminal vesicle origin must be nega-
tive for prostate specific antigen (PSA), prostatic acid
phosphatase (PAP) and preferably carcinoembryonic
antigen to be distinguished from prostatic and colorectal
carcinomas [1,4,5].
Seminal vesicle neoplasms are often difficult to diag-
nose, generally presenting as a retrovesical mass that
can be detected by digital rectal examination and
transrectal ultrasound. However, in roughly 30% of
patients no abnormalities on digital rectal examination
are detected due to concomitant benign prostatic hyper-
plasia obscuring the seminal vesicle tumor, or to loca-
tion of the tumor in the seminal vesicles are found [1].
In addition, computed tomography (CT) and magnetic
resonance imaging (MRI) improve the assessment of
seminal vesicle pathology.
Prognosis of patients with a seminal vesicle tumor is
generally poor. Early diagnosis may result in long-term
palliation or even cure. To date, no histopathological
prognostic factor could be identified and the estimate of
prognosis is challenging. Smith et al. state that seminal
vesicle carcinoma can run a rapidly fatal course or pos-
sess potential for cure [6]. Surgical procedures range
from local excision of a seminal vesicle to pelvic exen-
teration. As an adjuvant treatment, radiotherapy, che-
motherapy and hormonal manipulation are debated.
Case presentation
A 70-year-old Caucasian man was transferred to our
department from the Department of Neurology where
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he was an inpatient due to Lambert Eaton myasthenic
syndrome (LEMS).
LEMS is an autoimmune disease of the neuromuscular
junction, characterized by proximal muscle weakness,
areflexia and autonomic dysfunction. Antibodies are
found, directed against P/Q-type voltage gated calcium
channels in the pre-synaptic nerve terminal [7]. LEMS is
rare with a prevalence of about 1 per 100,000, equally
common in men and women. The onset is generally
over the age of 50, although it can affect children [8].
Lambert, Eaton, and Rooke in 1956 described a
myasthenic syndrome in association with lung cancer
[9]. Small cell lung carcinoma (SCLC) is found in over
half of patients [10]. There are also reports of an asso-
ciation with sarcoidosis and other autoimmune disorders
including vitiligo. There is an association with HLA-B8
and DR3 [8]. Due to the paraneoplastic etiology of
LEMS, CT is recommended at diagnosis.
In our case muscle weakness, an atactic gait, diplopic
images, dysphagia and ptosis were present. In retrospec-
tive view of our patient, the first symptoms of LEMS
were already present two and a half years earlier. At
that time our patient did not undergo medical examina-
tion and no further diagnostic workup was initiated.
After presenting at the Department of Neurology
other possible causes of LEMS were ruled out; internal
investigation was performed with findings of a hyperch-
olesterolemia. The medical history of our patient con-
tained a transurethral resection of the prostate gland
three years prior to treatment in our institution with
unsuspicious histological findings showing a chronic
prostatitis and benign hyperplasia. Additionally, our
patient was a smoker of 60 pack-years. There was no
evidence of autoimmune disease in the medical history.
Currently, no lower urinary tract symptoms and no loss
of weight or loss of appetite were described. The clinical
and ultrasound examinations were normal.
Subsequent radiologic evaluation by CT scan of the
cranium, thorax and abdomen did not show any sign of
malignant disease.
One year previously our patient was first sent to our
department for urogenital tumor search. No suspicious
findings were detected on digital rectal examination, like
the whole clinical and ultrasound examination of the
urogenital tract. PSA level was 0.8 ng/mL. To complete
the diagnosis a 10 core biopsy of the prostate gland was
performed that showed chronic prostatitis and benign
hyperplasia.
Whole body positron emission tomography (PET)/
low-dose CT scan (Figure 1) revealed a 2.3 × 1.9 cm
tumor of the right seminal vesicle presenting as an irre-
gular circumscribed mass. Furthermore, one lymph
node lateral to the tumor and numerous para-aortal and
right para-iliacal lymph nodes suspicious for metastases
were found. Additionally, a circumscribed mass of 2.5 ×
2.3 cm was detected in close contact to the psoas major
muscle. Cranium and thorax were clear of neoplasms on
CT and PET-CT.
Following the imaging results another transrectal
ultrasound-guided 10 core biopsy of the suspicious right
seminal vesicle and the right prostate gland was per-
formed.The histological findings of the biopsy of the
right seminal vesicle showed a poorly differentiated neu-
roendocrine carcinoma with immunohistochemistry
similar to SCLC. The immunohistochemistry was nega-
tive for PSA, positive for chromogranin A, synaptophy-
sin and CD99. Transcription termination factor TTF-1
was positive in about 60% of the tumor cells. A biopsy
of the right prostate gland showed chronic prostatitis
and a benign hyperplasia.
Having discussed all treatment options, our patient
underwent six cycles of chemotherapy with carboplatin
(520 mg) and etoposide (210 mg) at the Department of
Hemato-oncology. Additionally pyridostigmine bromide
60 mg twice daily and 90 mg during the night for the
myasthenic symptoms were initiated. With this medica-
tion the pronounced weakness that he initially presented
with declined.
Following six cycles of chemotherapy, our patient pre-
sented again to our department for re-evaluation. Sta-
ging was completed by a PET-CT scan (Figure 2), a CT
Figure 1 PET-CT scan, January 2008: Strong accumulation in
projection to the right seminal vesicle and the right parailiacal
lymph nodes.
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scan of the cranium, thorax and abdomen, and a trans-
rectal ultrasound.
The suspicious, enlarged para-aortal and para-iliacal
lymph nodes were stable. There was no evidence of new
metastases. A PET-CT scan showed a declining accumu-
lation in projection to the described para-aortal and
para-iliacal lymph nodes on both sides. Also a declining
accumulation in projection to the seminal vesicle was
described. The transrectal ultrasound of the prostate
and the seminal vesicles detected a hypoechoic 2.0 × 1.7
cm tumor in the right seminal vesicle. The biological
marker neuron-specific enolase declined from 72 μg/L
to 22 μg/L.
In cooperation with the Department of Hemato-oncol-
ogy, we decided a strategy of observation. Our patient
will re-present for re-evaluation for a two month follow-
up. In case of impairment of the clinical symptoms,
monotherapy with etoposide would be initiated.
Discussion
Primary tumors of seminal vesicles are rare. In the pre-
sent case a poorly differented neuroendocrine carcinoma,
a very rare entity, was confirmed by histopathology.
While this entity is known for sporadic primary tumors
of the prostate gland, cases of seminal vesicle involve-
ment are reported. Our patient presented with symptoms
of LEMS therefore a complete neurological, internal and
radiological investigation was carried out. Autoimmune
diseases could be excluded along with other neoplasms.
CT and PET-CT scan showed a tumor of the right semi-
nal vesicle as an irregular circumscribed mass. Numerous
lymph nodes suspicious for metastasis were detected.
Taking imaging results of the CT scans and the PET-CT
scans with the results of a mass in the right seminal vesi-
cle and ultrasound and subsequent biopsy findings into
consideration, a primary neuroendocrine carcinoma of
the seminal vesicle was diagnosed.
The aim of treatment of primary seminal vesicles is
curative radical surgery prior to any infiltration of neigh-
boring organs or even a metastatic disease. However,
hormonal manipulation and radiotherapy seem to be
effective as adjuvant treatment modalities [1]. Due to
the fact of histological findings of a poorly differented
neuroendocrine carcinoma with immunohistochemistry
similar to SCLC and the case of an advanced diseases
with evidence of lymph node metastasis we decided to
perform chemotherapy with carboplatin and etoposide.
While neuroendocrine carcinomas of the lung have
been described in association with LEMS, the present
case is the first description of this entity deriving from
seminal vesicles. Therapy of poorly differented neuroen-
docrine carcinoma is equivalent to therapy of SCLC.
Chemotherapy with carboplatin and etoposide is an
accepted treatment of choice for patients with advanced
SCLC [10]. Alternatively, a combination of gemcitabine
and carboplatin is possible. A randomised trial showed
gemcitabine/carboplatin as effective as carboplatin/eto-
poside in terms of overall survival and progression-free
survival and has a toxicity profile more acceptable to
patients [10].
Conclusions
Seminal vesicle tumors are rare. To the best of our
knowledge, we present the first case of a patient with
poorly differentiated neuroendocrine carcinoma of the
seminal vesicle diagnosed due to his presentation with
LEMS. The prognosis of a neuroendocrine carcinoma
with lymph node metastases is poor. In our case che-
motherapy with carboplatin and etoposide led to stable
disease, which was followed up by active surveillance.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
Figure 2 PET-CT scan, August 2008: declining accumulation in
projection to the right seminal vesicle and the right parailiacal
lymph nodes.
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